Why the study?
Does short-term beta-blockade with metoprolol or atenolol affect serum lipid levels and LDL interaction with arterial proteoglycans in healthy volunteers?
Does short-term beta-blockade with metoprolol or atenolol affect serum lipid levels and LDL interaction with arterial proteoglycans in healthy volunteers?
Short-term beta-blockade decreases LDL affinity for arterial proteoglycans, suggesting a potential anti-atherogenic mechanism despite adverse effects on HDL and triglycerides.
May not alter beta-blocker prescribing despite adverse lipid shifts; hypothesis-generating for reduced LDL-proteoglycan affinity as a potential anti-atherogenic effect.
In view of conflicting evidence suggesting that beta-blockers have an anti-atherogenic effect as well as induce a potentially atherogenic lipoprotein profile, the effects of a short term beta-blockade on serum lipoproteins were studied in 39 healthy volunteers. Because the interaction of LDL with arterial proteoglycans appears to play a role in lipoprotein accumulation during atherogenesis, the effects of metoprolol and atenolol on low density lipoprotein interaction with human aortic proteoglycans were included in the study. We could confirm that the beta-blockers caused a decrease in HDL cholesterol and an increase in triglycerides, both potentially undesirable effects. In addition, however they induced a significant decrease in the in vitro LDL affinity for arterial proteoglycans. Since there appears to be a strong association between LDL reactivity with proteoglycans and risk for myocardial infarction, this effect of the beta-blockers may be an anti-atherogenic effect which overrides other effects on the lipoprotein pattern.
No takes yet. Share an insight, caveat, or question.
LINDÉN et al. (1990) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: